Skip to main content
Erschienen in: Medical Oncology 1/2012

01.03.2012 | Original Paper

Association of β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 with the prognosis of esophageal squamous cell carcinoma

verfasst von: Jin Lv, Xiu-Feng Cao, Lv Ji, Bin Zhu, Dong-dong Wang, Lei Tao, Su-Qing Li

Erschienen in: Medical Oncology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

In our previous study, Human Signal Transduction in Cancer Gene Array was used in 12 fresh tumor samples to detect the gene expression profiles in the esophageal squamous cell carcinoma (ESCC) tissues matched adjacent non-cancerous samples. Among genes up-regulated at least twofold, β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 were found. So subsequently, the aim of this study was to investigate the prognosis and clinicopathologic roles of β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 in ESCC tissue. The mRNA and protein expression levels of β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 genes in 70 ESCC and adjacent non-cancerous paraffin-embedded samples were determined by Real-Time Quantitative PCR (RT-PCR) and immunohistochemical staining. The mRNA expression level of β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 in ESCC was significantly higher than that in the adjacent non-cancerous tissues (0.0821 ± 0.0416 vs. 0.0185 ± 0.0201, P = 0.0000; 1.9934 ± 1.9888 vs. 0.8863 ± 0.665, P = 0.0184; 0.0298 ± 0.0215 vs. 0.0189 ± 0.0187, P = 0.0017; 2.098 ± 0.091 vs. 1.016 ± 0.078, P = 0.0000; 2.181 ± 2.158 vs. 0.931 ± 0.894, P = 0.0152; respectively), and the protein expression level of determined genes was also significantly higher than that in the adjacent non-cancerous tissues (0.2835 ± 0.0844 vs. 0.2352 ± 0.0670, P = 0.0003; 0.3830 ± 0.0947 vs. 0.2721 ± 0.1474, P = 0.0000; 0.2637 ± 0.0348 vs. 0.2042 ± 0.0180, P = 0.0000; 0.2058 ± 0.0316 vs. 0.1218 ± 0.0518, P = 0.0000; 0.2736 ± 0.0834 vs. 0.2251 ± 0.0571, P = 0.0001; respectively). Then, the overexpression of mRNA and protein levels of β-catenin, Wnt1 and Bmi-1 was aggressively associated with lymph node metastasis, advanced pathological stage, and prognosis of the patients with ESCC (P < 0.05). The up-expression of Hoxa9 mRNA and protein was also aggressively associated with lymph node metastasis and advanced pathological stage (P < 0.05); however, the overexpression of Hoxa9 protein was not associated with the prognosis (P > 0.05). Meanwhile, the hypo-expression of Smad4 mRNA was aggressively associated with advanced pathological stage and prognosis of the patients with ESCC (P < 0.05); however, the hypo-expression of Smad4 protein was neutral to the prognosis and lymph node metastasis (P > 0.05). β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 protein expression analysis showed that the positive outcomes of the combined detection of Wnt1 and β-catenin expression or Wnt1, β-catenin and Bmi-1 expression were significantly worse than those of a single target protein expression (P < 0.05). Meantime, the prognosis of the combined positive expression of Wnt1, β-catenin, and Bmi-1 was poorer than that in the combined positive expression of Wnt1 and β-catenin (P < 0.05). The prognosis of ESCC patients with the overexpression of Wnt1/β-catenin and Bmi-1 was relatively poor, and the level of Wnt1/β-catenin and Bmi-1 was conversely correlated with advanced pathological stage and lymph node metastasis. The expression level of Smad4 and Hoxa9 mRNA was also associated with the prognosis of the patients with ESCC, pathological stage, and lymph node metastasis; however, they might not be the independent prognostic factor.
Literatur
2.
Zurück zum Zitat Greene FL, American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual. 6th ed. New York: Springer; 2002. p. 91–8. Greene FL, American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual. 6th ed. New York: Springer; 2002. p. 91–8.
3.
Zurück zum Zitat James RG, Conrad WH, Moon RT. Beta-catenin-independent Wnt pathways: signals, core proteins, and effectors. Methods Mol Biol. 2008;468:131–44.PubMedCrossRef James RG, Conrad WH, Moon RT. Beta-catenin-independent Wnt pathways: signals, core proteins, and effectors. Methods Mol Biol. 2008;468:131–44.PubMedCrossRef
4.
Zurück zum Zitat Corrigan PM, Dobbin E, Freeburn RW, et al. Patterns of Wnt/Fzd/LRP gene expression during embryonic hematopoiesis. Stem Cells Dev. 2009;18:759–72.PubMedCrossRef Corrigan PM, Dobbin E, Freeburn RW, et al. Patterns of Wnt/Fzd/LRP gene expression during embryonic hematopoiesis. Stem Cells Dev. 2009;18:759–72.PubMedCrossRef
5.
Zurück zum Zitat Fillmore RA, Mitra A, Xi Y, et al. Nmi (N-Myc interactor) inhibits Wnt/beta-catenin signaling and retards tumor growth. Int J Cancer. 2009;125:556–64.PubMedCrossRef Fillmore RA, Mitra A, Xi Y, et al. Nmi (N-Myc interactor) inhibits Wnt/beta-catenin signaling and retards tumor growth. Int J Cancer. 2009;125:556–64.PubMedCrossRef
6.
Zurück zum Zitat Matsubayashi S, Nakashima M, Kumagai K, et al. Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis. Pathol Res Pract. 2009;205:626–33.PubMedCrossRef Matsubayashi S, Nakashima M, Kumagai K, et al. Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis. Pathol Res Pract. 2009;205:626–33.PubMedCrossRef
7.
Zurück zum Zitat Clifford RL, Deacon K, Knox AJ. Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor (beta)1: requirement for Smads, (beta)-CATENIN, and GSK3 (beta). J Biol Chem. 2008;283:35337–53.PubMedCrossRef Clifford RL, Deacon K, Knox AJ. Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor (beta)1: requirement for Smads, (beta)-CATENIN, and GSK3 (beta). J Biol Chem. 2008;283:35337–53.PubMedCrossRef
8.
Zurück zum Zitat Tian X, Du H, Fu X, Li K, et al. Smad4 restoration leads to a suppression of Wnt/beta-catenin signaling activity and migration capacity in human colon carcinoma cells. Biochem Biophys Res Commun. 2009;380:478–83.PubMedCrossRef Tian X, Du H, Fu X, Li K, et al. Smad4 restoration leads to a suppression of Wnt/beta-catenin signaling activity and migration capacity in human colon carcinoma cells. Biochem Biophys Res Commun. 2009;380:478–83.PubMedCrossRef
9.
Zurück zum Zitat Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006;5:997–1014.PubMedCrossRef Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006;5:997–1014.PubMedCrossRef
10.
Zurück zum Zitat Dihlmann S, von Knebel Doeberitz M. Wnt/-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer. 2005;113:515–24.PubMedCrossRef Dihlmann S, von Knebel Doeberitz M. Wnt/-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer. 2005;113:515–24.PubMedCrossRef
11.
Zurück zum Zitat Huang M, Wang Y, Sun D, et al. Identification of genes regulated by Wnt/β-catenin pathway and involved in apoptosis via microarray analysis. BMC Cancer. 2006;6:221.PubMedCrossRef Huang M, Wang Y, Sun D, et al. Identification of genes regulated by Wnt/β-catenin pathway and involved in apoptosis via microarray analysis. BMC Cancer. 2006;6:221.PubMedCrossRef
12.
Zurück zum Zitat Winkel A, Stricker S, Tylzanowski P, et al. Wnt-ligand-dependent interaction of TAK1 (TGF-beta-activated kinase-1) with the receptor tyrosine kinase Ror2 modulates canonical Wnt-signalling. Cell Signal. 2008;20:2134–44.PubMedCrossRef Winkel A, Stricker S, Tylzanowski P, et al. Wnt-ligand-dependent interaction of TAK1 (TGF-beta-activated kinase-1) with the receptor tyrosine kinase Ror2 modulates canonical Wnt-signalling. Cell Signal. 2008;20:2134–44.PubMedCrossRef
13.
Zurück zum Zitat Verkaar F, van Rosmalen JW, Smits JF, et al. Stably overexpressed human Frizzled-2 signals through the beta-catenin pathway and does not activate Ca2+-mobilization in Human Embryonic Kidney 293 cells. Cell Signal. 2009;21:22–33.PubMedCrossRef Verkaar F, van Rosmalen JW, Smits JF, et al. Stably overexpressed human Frizzled-2 signals through the beta-catenin pathway and does not activate Ca2+-mobilization in Human Embryonic Kidney 293 cells. Cell Signal. 2009;21:22–33.PubMedCrossRef
14.
Zurück zum Zitat Lyu J, Yamamoto V, Lu W. Cleavage of the Wnt receptor Ryk regulates neuronal differentiation during cortical neurogenesis. Dev Cell. 2008;15:773–80.PubMedCrossRef Lyu J, Yamamoto V, Lu W. Cleavage of the Wnt receptor Ryk regulates neuronal differentiation during cortical neurogenesis. Dev Cell. 2008;15:773–80.PubMedCrossRef
15.
Zurück zum Zitat Katoh M, Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res. 2007;13:4042–5.PubMedCrossRef Katoh M, Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res. 2007;13:4042–5.PubMedCrossRef
16.
Zurück zum Zitat Paul S, Dey A. Wnt signaling and cancer development: therapeutic implication. Nat Rev Genet. 2008;55:165–76. Paul S, Dey A. Wnt signaling and cancer development: therapeutic implication. Nat Rev Genet. 2008;55:165–76.
17.
Zurück zum Zitat Herbst A, Kolligs FT. Wnt signaling as a therapeutic target for cancer. Methods Mol Biol. 2007;361:63–91.PubMed Herbst A, Kolligs FT. Wnt signaling as a therapeutic target for cancer. Methods Mol Biol. 2007;361:63–91.PubMed
18.
Zurück zum Zitat Mizushima T, Nakagawa H, Kamberov YG, et al. Wnt-1 but not epidermal growth factor induces β-catenin/T-cell factor-dependent transcription in esophageal cancer cells. Cancer Res. 2002;62:277–82.PubMed Mizushima T, Nakagawa H, Kamberov YG, et al. Wnt-1 but not epidermal growth factor induces β-catenin/T-cell factor-dependent transcription in esophageal cancer cells. Cancer Res. 2002;62:277–82.PubMed
19.
Zurück zum Zitat Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M, et al. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature (Lond). 1999;397:164–8.CrossRef Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M, et al. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature (Lond). 1999;397:164–8.CrossRef
20.
Zurück zum Zitat Nakanishi Y, Ochiai A, Akimoto S, et al. Expression of E-cadherin, apha - catenin, beta - catenin and plakoglobin in esophageal carcinomas and its prognostic significance: immunohistochemical analysis of 96 lesions. Oncology. 1997;54:158–65.PubMedCrossRef Nakanishi Y, Ochiai A, Akimoto S, et al. Expression of E-cadherin, apha - catenin, beta - catenin and plakoglobin in esophageal carcinomas and its prognostic significance: immunohistochemical analysis of 96 lesions. Oncology. 1997;54:158–65.PubMedCrossRef
21.
Zurück zum Zitat Krishnadath KK, Tilanus HW, Blankenstein MV, et al. Reduced expression of the cadherin—catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol. 1997;2:331–8.CrossRef Krishnadath KK, Tilanus HW, Blankenstein MV, et al. Reduced expression of the cadherin—catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol. 1997;2:331–8.CrossRef
22.
Zurück zum Zitat Osterheld MC, Bian YS, Bosman FT, et al. Beta—catenin expression and its association with prognostic factors in adenocarcinoma developed in Brrett esophagus. Am J Clin Pathol. 2002;117:451–6.PubMedCrossRef Osterheld MC, Bian YS, Bosman FT, et al. Beta—catenin expression and its association with prognostic factors in adenocarcinoma developed in Brrett esophagus. Am J Clin Pathol. 2002;117:451–6.PubMedCrossRef
23.
Zurück zum Zitat Yanagiswa J, Yanagi Y, Masuhire Y. Convergenece of transforming growth factor-p and vitamin D signaling pathways on SMAD transcriptional coactivators. Science. 1999;283:l3l7–21. Yanagiswa J, Yanagi Y, Masuhire Y. Convergenece of transforming growth factor-p and vitamin D signaling pathways on SMAD transcriptional coactivators. Science. 1999;283:l3l7–21.
24.
Zurück zum Zitat Fukuchi M, Masuda N, Miyazaki T, et al. Decreased Smad4 expression in the transforming growth factor-β signaling pathway during progression of esophageal squamous cell carcinoma. Cancer. 2002;95:737–43.PubMedCrossRef Fukuchi M, Masuda N, Miyazaki T, et al. Decreased Smad4 expression in the transforming growth factor-β signaling pathway during progression of esophageal squamous cell carcinoma. Cancer. 2002;95:737–43.PubMedCrossRef
25.
Zurück zum Zitat Takahashi O, Hamada J-I, Abe M, et al. Dysregulated expression of HOX and ParaHOX genes in human esophageal squamous cell carcinoma. Oncology Reports. 2007;17:753–60.PubMed Takahashi O, Hamada J-I, Abe M, et al. Dysregulated expression of HOX and ParaHOX genes in human esophageal squamous cell carcinoma. Oncology Reports. 2007;17:753–60.PubMed
26.
Zurück zum Zitat Cillo C, Barba P, Freschi G, et al. HOX gene expression in normal and neoplastichuman kidney. Int J Cancer. 1992;51:892–7.PubMedCrossRef Cillo C, Barba P, Freschi G, et al. HOX gene expression in normal and neoplastichuman kidney. Int J Cancer. 1992;51:892–7.PubMedCrossRef
27.
Zurück zum Zitat De Vita G, Barba P, Odartchenko N, et al. Expressionof homeobox-containing genes in primary and metastaticcolorectal cancer. Eur J Cancer. 1993;29A:887–93.PubMed De Vita G, Barba P, Odartchenko N, et al. Expressionof homeobox-containing genes in primary and metastaticcolorectal cancer. Eur J Cancer. 1993;29A:887–93.PubMed
28.
Zurück zum Zitat Cantile M, Cindolo L, Napodano G, et al. Hyperexpression of locus C genes in the HOX network is strongly associated in vivo with human bladder transitional cell carcinomas. Oncogene. 2003;22:6462–8.PubMedCrossRef Cantile M, Cindolo L, Napodano G, et al. Hyperexpression of locus C genes in the HOX network is strongly associated in vivo with human bladder transitional cell carcinomas. Oncogene. 2003;22:6462–8.PubMedCrossRef
29.
Zurück zum Zitat Waltregny D, Alami Y, Clausse N, et al. Overexpression of the homeobox gene HOXC8 in human prostate cancer correlates with loss of tumor differentiation. Prostate. 2002;50:162–9.PubMedCrossRef Waltregny D, Alami Y, Clausse N, et al. Overexpression of the homeobox gene HOXC8 in human prostate cancer correlates with loss of tumor differentiation. Prostate. 2002;50:162–9.PubMedCrossRef
30.
Zurück zum Zitat Hamada J, Omatsu T, Okada F, et al. Overexpression of homeobox gene HOXD3 induces coordinate expression of metastasis- related genes in human lung cancer cells. Int J Cancer. 2001;93:516–25.CrossRef Hamada J, Omatsu T, Okada F, et al. Overexpression of homeobox gene HOXD3 induces coordinate expression of metastasis- related genes in human lung cancer cells. Int J Cancer. 2001;93:516–25.CrossRef
31.
Zurück zum Zitat Maeda K, Hamada J, Takahashi Y, et al. Altered expressions of HOX genes in human cutaneous malignant melanoma. Int J Cancer. 2005;114:436–41.PubMedCrossRef Maeda K, Hamada J, Takahashi Y, et al. Altered expressions of HOX genes in human cutaneous malignant melanoma. Int J Cancer. 2005;114:436–41.PubMedCrossRef
Metadaten
Titel
Association of β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 with the prognosis of esophageal squamous cell carcinoma
verfasst von
Jin Lv
Xiu-Feng Cao
Lv Ji
Bin Zhu
Dong-dong Wang
Lei Tao
Su-Qing Li
Publikationsdatum
01.03.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9816-5

Weitere Artikel der Ausgabe 1/2012

Medical Oncology 1/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.